Table 3. Laboratory analyses on children with juvenile idiopathic arthritis who were treated with tocilizumab.

Parameters	At onset of tocilizumab use* Median (range)	After tocilizumab use* Median (range)	P-value
Hemoglobin, g/dl	11.3 (10.0-11.9)	12.5 (12.15-13.10)	< 0.01
White blood cells, 109 cells/l	11.5 (10.1-17.5)	7.29 (5.43-8.70)	< 0.01
Granulocyte count	8.22 (6.92-10.19)	3.07 (2.29-4.88)	< 0.01
Lymphocyte count	2.3 (1.18-4.6)	2.47 (1.67-3.09)	0.859
Platelet count, 109/l	457 (345-536)	278 (243-285)	0.021
Mean platelet volume, fl	7.3 (6.8-7.8)	7.9 (7.3-8.1)	0.046
Alanine aminotransferase level, U/l	12 (10-23)	15 (13-18)	0.895
C-reactive protein level (mg/l)*	45.6 (17.3-101)	3.1 (< 3.1)	< 0.01
Erythrocyte sedimentation rate (mm/hour)	42 (30-48)	3 (2-5)	< 0.01

*In our laboratory, the lowest measurable C-reactive protein (CRP) value was < 3.1 mg/l. CRP level after tocilizumab treatment was < 3.1 mg/l in all patients.